Adjunctive Use of Phage Sb-1 in Antibiotics Enhances Inhibitory Biofilm Growth Activity versus Rifampin-Resistant Staphylococcus aureus Strains
- PMID: 33138034
- PMCID: PMC7692760
- DOI: 10.3390/antibiotics9110749
Adjunctive Use of Phage Sb-1 in Antibiotics Enhances Inhibitory Biofilm Growth Activity versus Rifampin-Resistant Staphylococcus aureus Strains
Abstract
Effective antimicrobials are crucial for managing Staphylococcus aureus implant-associated bone infections (IABIs), particularly for infections due to rifampin-resistant S. aureus (RRSA). Failure to remove the implant results in persistent infection; thus, prolonged suppressive antibiotic therapy may be a reasonable alternative. However, a high incidence of adverse events can necessitate the discontinuation of therapy. In this scenario, commercial Staphylococcal bacteriophage Sb-1 combined with antibiotics is an option, showing a promising synergistic activity to facilitate the treatment of biofilm infections. Therefore, we evaluated the efficacy of the inhibitory activity of five antibiotics (doxycycline, levofloxacin, clindamycin, linezolid, and rifampin) alone or combined with phage Sb-1 (106 PFU/mL) in a simultaneous and staggered manner, to combat five clinical RRSA strains and the laboratory strain MRSA ATCC 43300 in 72 h by isothermal microcalorimetry. The synergistic effects were observed when phage Sb-1 (106 PFU/mL) combined with antibiotics had at least 2 log-reduction lower concentrations, represented by a fractional biofilm inhibitory concentration (FBIC) of <0.25. Among the antibiotics that we tested, the synergistic effect of all six strains was achieved in phage/doxycycline and phage/linezolid combinations in a staggered manner, whereas a distinctly noticeable improvement in inhibitory activity was observed in the phage/doxycycline combination with a low concentration of doxycycline. Moreover, phage/levofloxacin and phage/clindamycin combinations also showed a synergistic inhibitory effect against five strains and four strains, respectively. Interestingly, the synergistic inhibitory activity was also observed in the doxycycline-resistant and levofloxacin-resistant profile strains. However, no inhibitory activity was observed for all of the combinations in a simultaneous manner, as well as for the phage/rifampin combination in a staggered manner. These results have implications for alternative, combined, and prolonged suppressive antimicrobial treatment approaches.
Keywords: antibiotic-phage combination; biofilm infection; rifampin-resistant Staphylococcus aureus; suppression therapy; synergism.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Evaluation of Staphylococcal Bacteriophage Sb-1 as an Adjunctive Agent to Antibiotics Against Rifampin-Resistant Staphylococcus aureus Biofilms.Front Microbiol. 2020 Nov 11;11:602057. doi: 10.3389/fmicb.2020.602057. eCollection 2020. Front Microbiol. 2020. PMID: 33262752 Free PMC article.
-
Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus.Int J Antimicrob Agents. 2018 Dec;52(6):842-853. doi: 10.1016/j.ijantimicag.2018.09.006. Epub 2018 Sep 17. Int J Antimicrob Agents. 2018. PMID: 30236955
-
[In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].Rev Esp Quimioter. 2005 Jun;18(2):168-72. Rev Esp Quimioter. 2005. PMID: 16130039 Spanish.
-
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.Pediatr Pulmonol. 2020 Jan;55(1):33-57. doi: 10.1002/ppul.24537. Epub 2019 Oct 14. Pediatr Pulmonol. 2020. PMID: 31609097 Review.
-
Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections.Front Mol Biosci. 2021 Apr 29;8:654038. doi: 10.3389/fmolb.2021.654038. eCollection 2021. Front Mol Biosci. 2021. PMID: 33996906 Free PMC article. Review.
Cited by
-
Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections.Microbiol Spectr. 2024 Jan 11;12(1):e0321923. doi: 10.1128/spectrum.03219-23. Epub 2023 Dec 12. Microbiol Spectr. 2024. PMID: 38084971 Free PMC article.
-
Biothermodynamics of Viruses from Absolute Zero (1950) to Virothermodynamics (2022).Vaccines (Basel). 2022 Dec 9;10(12):2112. doi: 10.3390/vaccines10122112. Vaccines (Basel). 2022. PMID: 36560522 Free PMC article. Review.
-
Development of Effective Antibacterial Treatment: Lessons from the Past and Novel Approaches.Antibiotics (Basel). 2021 Feb 25;10(3):230. doi: 10.3390/antibiotics10030230. Antibiotics (Basel). 2021. PMID: 33668709 Free PMC article.
-
The SARS-CoV-2 Hydra, a tiny monster from the 21st century: Thermodynamics of the BA.5.2 and BF.7 variants.Microb Risk Anal. 2023 Apr;23:100249. doi: 10.1016/j.mran.2023.100249. Epub 2023 Feb 4. Microb Risk Anal. 2023. PMID: 36777924 Free PMC article.
-
Considerations for the Use of Phage Therapy in Clinical Practice.Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0207121. doi: 10.1128/AAC.02071-21. Epub 2022 Jan 18. Antimicrob Agents Chemother. 2022. PMID: 35041506 Free PMC article. Review.
References
-
- Moriarty T.F., Kuehl R., Coenye T., Metsemakers W.J., Morgenstern M., Schwarz E.M., Riool M., Zaat S.A.J., Khana N., Kates S.L., et al. Orthopaedic device-related infection: Current and future interventions for improved prevention and treatment. Efort Open Rev. 2016;1:89–99. doi: 10.1302/2058-5241.1.000037. - DOI - PMC - PubMed
-
- Kolenda C., Josse J., Medina M., Fevre C., Lustig S., Ferry T., Laurent F. Evaluation of the Activity of a Combination of Three Bacteriophages Alone or in Association with Antibiotics on Staphylococcus aureus Embedded in Biofilm or Internalized in Osteoblasts. Antimicrob. Agents Chemother. 2020;64 doi: 10.1128/AAC.02231-19. - DOI - PMC - PubMed
-
- Murillo O., Pachón M.E., Euba G., Verdaguer R., Tubau F., Cabellos C., Cabo J., Gudiol F., Ariza J. Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection. Antimicrob. Agents Chemother. 2008;52:3681–3686. doi: 10.1128/AAC.00458-08. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Molecular Biology Databases